These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28609518)

  • 1. Brain Amyloid Pathology and Cognitive Function: Alzheimer Disease Without Dementia?
    Visser PJ; Tijms B
    JAMA; 2017 Jun; 317(22):2285-2287. PubMed ID: 28609518
    [No Abstract]   [Full Text] [Related]  

  • 2. β-Amyloidosis and neurodegeneration in Alzheimer disease: who's on first?
    Knopman DS
    Neurology; 2014 May; 82(20):1756-7. PubMed ID: 24748669
    [No Abstract]   [Full Text] [Related]  

  • 3. Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms.
    Hampel H
    J Alzheimers Dis; 2013; 33 Suppl 1():S79-86. PubMed ID: 22531423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is amyloid-β harmful to the brain? Insights from human imaging studies.
    Jagust W
    Brain; 2016 Jan; 139(Pt 1):23-30. PubMed ID: 26614753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lecanemab reduces brain amyloid-β and delays cognitive worsening.
    Knopman DS
    Cell Rep Med; 2023 Mar; 4(3):100982. PubMed ID: 36948153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.
    Butterfield DA; Reed T; Newman SF; Sultana R
    Free Radic Biol Med; 2007 Sep; 43(5):658-77. PubMed ID: 17664130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postischemic dementia with Alzheimer phenotype: selectively vulnerable versus resistant areas of the brain and neurodegeneration versus β-amyloid peptide.
    Pluta R; Jabłoński M; Czuczwar SJ
    Folia Neuropathol; 2012; 50(2):101-9. PubMed ID: 22773455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of brain amyloid in dementia: a review.
    Quigley H; Colloby SJ; O'Brien JT
    Int J Geriatr Psychiatry; 2011 Oct; 26(10):991-9. PubMed ID: 21905095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical Activity and Amyloid-β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment.
    de Souto Barreto P; Andrieu S; Payoux P; Demougeot L; Rolland Y; Vellas B;
    J Am Geriatr Soc; 2015 Aug; 63(8):1634-9. PubMed ID: 26200930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fallacy of amyloid and cognition in Alzheimer's disease.
    Lee HG; Zhu X; Perry G; Smith MA
    Drugs Aging; 2006; 23(2):179. PubMed ID: 16536639
    [No Abstract]   [Full Text] [Related]  

  • 13. Cognitive reserve and β-amyloid pathology in Parkinson disease.
    Lucero C; Campbell MC; Flores H; Maiti B; Perlmutter JS; Foster ER
    Parkinsonism Relat Disord; 2015 Aug; 21(8):899-904. PubMed ID: 26037458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment.
    Dao E; Hsiung GY; Sossi V; Jacova C; Tam R; Dinelle K; Best JR; Liu-Ambrose T
    BMC Neurol; 2015 Oct; 15():197. PubMed ID: 26459220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive 'Brain Training' Intervention Fails to Reduce Amyloid Pathologies or Cognitive Deficits in Transgenic Mouse Models of Alzheimer's Disease.
    Anderson M; Xu F; Ou-Yang MH; Davis J; Van Nostrand WE; Robinson JK
    J Alzheimers Dis; 2017; 55(3):1109-1121. PubMed ID: 27767989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical activity and AD-related pathology.
    Wang HX
    Arch Neurol; 2012 Jul; 69(7):940-1; author reply 941. PubMed ID: 22777267
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain amyloid imaging.
    Rowe CC; Villemagne VL
    J Nucl Med Technol; 2013 Mar; 41(1):11-8. PubMed ID: 23396994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular pathology of Alzheimer's disease.
    Harrington CR
    Neuroimaging Clin N Am; 2012 Feb; 22(1):11-22, vii. PubMed ID: 22284730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent cognitive status with the same Braak stage of neurofibrillary pathology: does the pattern of amyloid-β deposits make the difference?
    Maderna E; Cattaneo C; Cacciatore F; Catania M; Di Fede G; Tagliavini F; Giaccone G
    J Alzheimers Dis; 2015; 43(2):375-9. PubMed ID: 25096620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.